Rafarma Pharmaceuticals Return On Equity vs. Current Valuation
| RAFA Stock | USD 0.09 0.03 47.54% |
For Rafarma Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rafarma Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rafarma Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rafarma Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rafarma Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rafarma |
Rafarma Pharmaceuticals Current Valuation vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rafarma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rafarma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Rafarma Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It is rated third in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rafarma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rafarma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Rafarma Current Valuation vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Rafarma Pharmaceuticals |
| = | -7.0E-4 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Rafarma Pharmaceuticals |
| = | 7.89 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Rafarma Current Valuation vs Competition
Rafarma Pharmaceuticals is rated third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 496.16 Million. Rafarma Pharmaceuticals claims roughly 7.89 Million in current valuation contributing just under 2% to equities under Drug Manufacturers—Specialty & Generic industry.
Rafarma Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rafarma Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rafarma Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Rafarma Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Rafarma Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Rafarma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rafarma Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rafarma Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rafarma Pharmaceuticals' important profitability drivers and their relationship over time.
Use Rafarma Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rafarma Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rafarma Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Rafarma Pharmaceuticals Pair Trading
Rafarma Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Rafarma Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rafarma Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rafarma Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rafarma Pharmaceuticals to buy it.
The correlation of Rafarma Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rafarma Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rafarma Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rafarma Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Rafarma Pharmaceuticals position
In addition to having Rafarma Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate ETFs Thematic Idea Now
Real Estate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 65 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Rafarma Pink Sheet
To fully project Rafarma Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Rafarma Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Rafarma Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.